福辛普利对原发性高血压患者降钙素基因相关肽血浆浓度的影响

Effect of fosinopril on the plasma level of calcitonin gene-related peptide in patients with essential hypertension

目的 :观察血管紧张素转换酶抑制剂福辛普利对轻、中度原发性高血压患者的降压作用及其对降钙素基因相关肽 (CGRP)释放的影响。方法 :采用自身前后对照方法。 30例轻、中度原发性高血压患者服用福辛普利4周 ,剂量 10～ 4 0mg/d ,分别于治疗前、治疗中 (服药d 5 )、治疗后 (服药d 30 )测定血压及血浆CGRP浓度。 结果 :原发性高血压患者经福辛普利治疗后 ,d 5、d 30血压均较治疗显著下降 (均P <0 .0 1) ,同时血浆CGRP浓度均显著升高 (均P <0 .0 1) ;血压的下降幅度与血浆CGRP浓度变化呈显著正相关 (γ =0 .5 79,P <0 .0 1)。结论 :福辛普利能显著降低轻、中度原发性高血压患者的血压 ,同时能升高血浆CGRP浓度 ;福辛普利促进CGRP释放可能是其降压机制之一。

Objective:To investigate the antihypertensive effect of fosinopril,an inhibitor of angiotension converting enzyme,and its effect on the plasma calcitonin gene related peptide(CGRP)concentration in patients with mild or moderate essential hypertension.Methods:30 patients with mild or moderate essential hypertension were treated with fosinopril in a titration manner,10 40 mg/d,given orally for 4 weeks. Blood pressure and plasma concentrations of CGRP were measured.Results:In patients with mild or moderate essential hypertension, fosinopril significantly decreased blood pressure 5 days and 30 days after treatment( P <0.01) concomitantly with an increase in plasma concentrations of CGRP( P <0.01).And there is a positive correlation between the decrease of blood pressure and increase of plasma concentration of CGRP.Conclusion:Fosinopril has significant antihypertensive effect in patients with mild or moderate essential hypertension concomitantly with an increase of plasma concentrations of CGRP, and the antihypertensive effect of fosinopril may be related to stimulation of CGRP release.